AstraZeneca Annual Report and IFRS Restatements Form 20-F Information 2004 139 IFRS Restatements Introduction to be taken directly to reserves, as is payments and milestones, are capitalised AstraZeneca currently prepares its primary required under FRS 17 Retirement and amortised over their economic lives from financial statements under UK Generally Benefits.
Intangible assets relating to products Accepted Accounting Principles UK GAAP.
endorsed by the EU, will be effective for in development both internally generated From 2005 onwards the Group will be accounting periods commencing on or and externally acquired are subject to required to prepare its consolidated financial after 1 January 2006, with earlier impairment testing at each balance sheet statements in accordance with International adoption encouraged by the IASB.
date or earlier upon indication of impairment.
Accounting Standards IAS and International AstraZeneca has adopted the provisions Any impairment losses are written off Financial Reporting Standards IFRS as of this amendment in its restated immediately to income.
adopted by the European Union EU.
change applies to all financial reporting for IFRS 2, IFRS 6 and various IFRIC Business combinations and goodwill accounting periods beginning on or after interpretations and amendments to On the acquisition of a business, fair values 1 January 2005 and, consequently, SIC 12 have not yet been endorsed.
are attributed to the net assets acquired.
AstraZenecas first IFRS results will be its Goodwill arises where the fair value of the interim results for Q1 2005.
The Groups first Accounting policies consideration given for a business exceeds Annual Report under IFRS will be for 2005. the fair value of such net assets.
As the Group publishes comparative Basis of accounting information for two years in its Annual As set out in the Basis of Preparation, the Goodwill arising on acquisitions is capitalised Report, the date for transition to IFRS is restated financial information on pages 139 and subject to impairment review, both 1 January 2003, this being the start of the to 146, has been prepared in accordance annually and when there are indications that earliest period of comparative information.
with IAS and IFRS as adopted by the EU.
the carrying value may not be recoverable.
Prior to 1 January 2003, goodwill was To explain how AstraZenecas reported The accounting policy for financial amortised over its estimated useful life: such performance and financial position are instruments complies with the EU carve out amortisation ceased on 31 December 2002. affected by this change, information version of IAS 39.
The policies also assume previously published under UK GAAP is that the amendments to IAS 19 Employee The Groups policy up to and including 1997 restated under IFRS on pages 139 to 146.
Benefits published in December 2004 by the was to eliminate goodwill arising upon IASB, allowing actuarial gains and losses to acquisitions against reserves.
Under IFRS 1 As noted below, these financial statements be recognised in full through reserves, will be and IFRS 3, such goodwill will remain have been prepared on the basis of IFRSs endorsed by the EU.
expected to be available at 31 December 2005.
These are subject to ongoing review AstraZenecas management considers the Employee benefits and endorsement by the EU or possible following to be the most important The Group accounts for pensions and similar amendment by interpretative guidance from accounting policies in the context of the benefits principally healthcare under IAS 19 the IASB International Accounting Groups operations.
In respect of defined Standards Board and are therefore still benefit plans, obligations are measured at subject to change.
We will update our Revenue discounted present value whilst plan assets restated information as necessary for any Turnover excludes inter-company sales and are recorded at fair value.
The operating and such changes, should they occur.
value-added taxes and represents net financing costs of such plans are recognised invoice value less estimated rebates, returns separately in the income statement: service Basis of preparation and settlement discounts.
Turnover is costs are spread systematically over the lives The financial information has been prepared recognised when the significant risks and of employees and financing costs are in accordance with IFRS as adopted by the rewards of ownership have been transferred recognised in the periods in which they arise.
The accounting policies applied are set to a third party.
Actuarial gains and losses are recognised out on pages 139 to 141. immediately in the statement of recognised Research and development income and expense.
All IASB standards in issue at December Research expenditure is charged to income 2004 have been endorsed by the EU, except in the year in which it is incurred.
Payments to defined contribution schemes as noted below: are charged as an expense as they fall due.
Internal development expenditure is charged The EU has issued a revised version of to income in the year in which it is incurred Share-based payments IAS 39 referred to as the carve out unless it meets the recognition criteria of IAS The fair value of employee share option plans version and has endorsed this rather 38 Intangible Assets.
Regulatory and other is calculated using the Black-Scholes model.
than the full IASB standard.
uncertainties generally mean that such In accordance with IFRS 2 Share-based The IASB has issued amendments to criteria are not met.
Where, however, the Payments the resulting cost is charged to IAS 19 allowing actuarial gains or losses recognition criteria are met, intangible assets the income statement over the vesting period are capitalised and amortised over their of the options.
The value of the charge is References to IFRS refer to the application of useful economic lives from product launch.
adjusted to reflect expected and actual levels International Accounting Standards, Payments to in-license products and of options vesting.
International Financial Reporting Standards compounds from external third parties, and Standing Interpretations issued by the International Financial Reporting generally taking the form of up-front Interpretations Committee IFRIC.
AstraZeneca Annual Report and IFRS Restatements 140 Form 20-F Information 2004 IFRS Restatements continued Foreign currencies Tangible fixed assets is included in the Group income statement Profit and loss accounts in foreign currencies The Groups policy is to write off the on the equity accounting basis.
The holding are translated into US dollars at average difference between the cost of each tangible value of significant associates and joint exchange rates for the relevant accounting fixed asset and its residual value ventures in the Group balance sheet is periods.
Assets and liabilities are translated systematically over its estimated useful life.
calculated by reference to AstraZenecas at exchange rates prevailing at the date of the Reviews are made annually of the estimated equity in the net assets of such associates Group balance sheet.
remaining lives and residual values of and joint ventures, as shown by the most individual productive assets, taking account recent accounts available, adjusted where Exchange gains and losses on short term of commercial and technological appropriate and including goodwill on foreign currency borrowings and deposits obsolescence as well as normal wear and acquisitions made since 1 January 1998. are included within net interest payable.
Under this policy it becomes impractical Exchange differences on all other to calculate average assets lives exactly.
Contingent liabilities transactions, except relevant foreign However, the total lives range from Through the normal course of business, currency loans, are taken to operating profit.
approximately 13 to 50 years for buildings, AstraZeneca is involved in legal disputes, the In the consolidated financial statements, and three to 15 years for plant and settlement of which may involve cost to the exchange differences arising on equipment.
All tangible fixed assets are Group.
Provision is made where an adverse consolidation of the net investments in reviewed for impairment when there are outcome is probable and associated costs subsidiaries, joint ventures and associates, indications that the carrying value may not be can be estimated reliably.
together with those on relevant foreign recoverable.
currency loans, are taken directly to reserves AstraZeneca is exposed to environmental via the statement of recognised income and Leases liabilities relating to its past operations, expense.
Assets held under finance leases are principally in respect of soil and groundwater capitalised and included in tangible fixed remediation costs.
Provisions for these costs Taxation assets at fair value.
Each asset is depreciated are made when there is a present obligation The charge for taxation is based on the over the shorter of the lease term or its useful and where it is probable that expenditure on profits for the year and takes into account life.
The obligations related to finance leases, remedial work will be required and that a taxation deferred because of temporary net of finance charges in respect of future reliable estimate can be made of the cost.
differences between the treatment of certain periods, are included, as appropriate, under items for taxation and for accounting creditors due within, or creditors due after Inventories purposes.
Full provision is made for the tax more than, one year.
The interest element of Inventories are stated at the lower of cost or effects of these differences.
Deferred tax the rental obligation is allocated to net realisable value.
The first in, first out or an assets are recognised to the extent that it is accounting periods during the lease term to average method of valuation is used.
For probable that taxable profit will be available reflect a constant rate of interest on the finished goods and work in progress, cost against which the asset can be utilised.
This remaining balance of the obligation for each includes directly attributable costs and requires judgements to be made in respect of accounting period.
certain overhead expenses including the forecast of future taxable income.
Selling expenses and certain Rentals under operating leases are charged other overhead expenses principally central No deferred tax asset or liability is recognised to the income statement as incurred.
Net in respect of temporary differences realisable value is determined as estimated associated with investments in subsidiaries, Subsidiaries, associates and joint ventures selling price less all estimated costs of branches, associates and joint ventures, A subsidiary is an entity controlled, directly or completion and costs to be incurred in where the Group is able to control the timing indirectly, by AstraZeneca PLC.
Control is marketing, selling and distribution.
of reversal of the temporary differences and it regarded as the power to govern the financial is probable that the temporary differences will and operating policies of the entity so as to Financial instruments not reverse in the foreseeable future.
obtain benefits from its activities.
Financial instruments are recorded initially at fair value.
Subsequent measurement Accruals for tax contingencies require An associate is an undertaking, not being a depends on the designation of the management to make judgements and subsidiary or joint venture, in which instrument, as follows: estimates of ultimate exposures in relation to AstraZeneca has a participating interest and tax audit issues and exposures.
Tax benefits over whose commercial and financial policy Investments other than interests in joint are not recognised unless the tax positions decisions AstraZeneca has the power to ventures, associates and fixed deposits will probably be sustained.
Once considered exert significant influence.
and short term investments other than to be probable, management reviews each fixed deposits are normally designated material tax benefit to assess whether a A joint venture is an entity in which as available for sale.
Where the exposure provision should be taken against full AstraZeneca holds an interest on a long term to a change in fair value of such an asset recognition of that benefit on the basis of a basis and which is jointly controlled by is substantially offset by the exposure to potential settlement through negotiation AstraZeneca and one or more other a change in the fair value of derivatives, and or litigation.
Any recorded exposure to venturers under a contractual arrangement.
the asset is generally classified as fair the interest on tax liabilities is provided for in value through profit or loss.
AstraZenecas share of the profit less losses of all significant joint ventures and associates Fixed deposits, comprising principally AstraZeneca Annual Report and IFRS Restatements Form 20-F Information 2004 141 funds held with banks and other financial In addition the Group has chosen to restate institutions, and short term borrowings comparative information with respect to and overdrafts are classified as loans and IAS 32, IAS 39 and IFRS 2. receivables and held at amortised cost.
The Group has also opted to adopt the IASB Derivatives, comprising interest rate amendments to IAS 19 early, allowing swaps, foreign exchange contracts and actuarial gains and losses to be charged to options and embedded derivatives, are reserves in the period in which they arise.
classified as held for trading.
Changes in fair value are taken to the income statement.
Long term loans are generally held at amortised cost.
Where a derivative financial instrument generally an interest rate swap hedges the changes in fair value of a long term loan, any gain or loss on the hedging instrument is recognised in the income statement.
The hedged item is also stated at fair value in respect of the risk being hedged, with any gain or loss being recognised in the income statement.
Changes in the fair value of financial instruments are dealt with as follows: For available for sale assets, exchange losses and impairments are taken to the income statement.
All other changes in fair value are taken to reserves.
On disposal of the related asset, the accumulated changes in fair value recorded in reserves are included in the gain or loss recorded in the income statement.
For long term loans effectively hedged, assets at fair value through profit or loss and assets held for trading, all changes in fair value are recognised in the income statement.
IFRS transitional arrangements and early adoption When preparing the Groups IFRS balance sheet at 1 January 2003, the date of transition, the following optional exemptions from full retrospective application of IFRS accounting policies have been adopted: Business combinations the provisions of IFRS 3 have been applied prospectively from 1 January 2003: and Employee benefits the accumulated actuarial gains and losses in respect of employee defined benefit plans have been recognised in full through reserves.
AstraZeneca Annual Report and IFRS Restatements 142 Form 20-F Information 2004 IFRS Restatements continued Reconciliation of profit IFRS 2 IAS 32 Reported ShareIAS 19 IAS 39 Restated under UK based Employee Financial under GAAP Payments Benefits Instruments Other IFRS For the year ended 31 December 2004 $m $m $m $m $m $m Sales 21,42621,426 Cost of sales 5,150 2 41 5,193 Distribution costs 177 177 Research and development 3,803 42 1 24 403 3,467 Selling, general and administrative expenses 7,841 103 10 334 8,268 Other operating income 315 89 226 Operating profit 4,770 147 9 154 69 4,547 Net finance costs 90 8 28 1 53 Income from dividends 6 6 Profit on sale of interest in joint venture 219 219 Profit before tax 5,085 147 1 182 68 4,825 Taxation 1,254 20 1 54 66 1,155 Profit for the period 3,831 167 128 134 3,670 Attributable to: Equity holders of the Company 3,813 167 1 128 134 3,651 Minority interest 18 1 19 Basic earnings per $0.25 Ordinary Share $2.28 $0.10 $0.00 $0.08 $0.08 $2.18 Diluted earnings per $0.25 Ordinary Share $2.28 $0.10 $0.00 $0.08 $0.08 $2.18 Statement of Recognised Income and Expense For the year ended 31 December 2004 $m Net profit for the period 3,651 Foreign exchange adjustments on consolidation 689 Tax on foreign exchange adjustments 379 Valuation gains taken to equity 39 Actuarial gains and losses, net of tax 98 Recognised gains and losses for the year 4,660 Tax on foreign exchange adjustments on consolidation in 2004 includes a credit of $357m in respect of foreign exchange losses arising in 2000.
AstraZeneca Annual Report and IFRS Restatements Form 20-F Information 2004 143 Reconciliation of profit IFRS 2 IAS 32 Reported ShareIAS 19 IAS 39 Restated under UK based Employee Financial under GAAP Payments Benefits Instruments Other IFRS For the year ended 31 December 2003 $m $m $m $m $m $m Sales 18,849 18,849 Cost of sales 4,469 2 2 11 1 4,463 Distribution costs 162 162 Research and development 3,451 42 5 486 3,012 Selling, general and administrative expenses 6,856 110 7 4 424 7,393 Other operating income 200 12 188 Operating profit 4,111 154 14 3 61 4,007 Net finance costs 89 7 24 2 56 Income from dividends 2 2 Profit before tax 4,202 154 21 21 59 4,065 Taxation 1,143 18 6 5 85 1,029 Profit for the year 3,059 136 15 16 144 3,036 Attributable to: Equity holders of the Company 3,036 136 14 16 144 3,014 Minority interest 23 1 22 Basic earnings per $0.25 Ordinary Share $1.78 $0.08 $0.01 $0.01 $0.08 $1.76 Diluted earnings per $0.25 Ordinary Share $1.78 $0.08 $0.01 $0.01 $0.08 $1.76 Statement of Recognised Gains and Losses For the year ended 31 December 2003 $m Net profit for the period 3,014 Foreign exchange adjustments on consolidation 1,256 Tax on foreign exchange adjustments 66 Valuation gains taken to equity 10 Actuarial gains and losses, net of tax 167 Recognised gains and losses for the year 4,179 AstraZeneca Annual Report and IFRS Restatements 144 Form 20-F Information 2004 IFRS Restatements continued Reconciliation of equity IAS 32 Reported IAS 19 IAS 39 IAS 12 under UK Employee Financial Income Restated GAAP Benefits Instruments Tax Other under IFRS As at 31 December 2004 $m $m $m $m $m $m Assets Non-current assets Property, plant and equipment 8,083 14 8,097 Goodwill and intangible assets 2,826 224 3,050 Other investments 267 5 262 Deferred tax assets 548 31 1,016 1 1,594 11,176 548 26 1,016 237 13,003 Current assets Inventories 3,020 3,020 Trade and other receivables 6,274 720 781 2 4,771 Short term investments, cash and cash equivalents 5,146 88 5,234 14,440 720 88 781 2 13,025 Total assets 25,616 172 114 235 235 26,028 Liabilities Current liabilities Short term borrowings, overdrafts and current instalments of loans 142 142 Other creditors 7,640 111 25 1,059 6,445 7,782 111 25 1,059 6,587 Non-current liabilities Loans 1,030 68 1,098 Retirement benefit obligations 1,761 1,761 Provisions and deferred tax liabilities 2,207 387 43 107 8 1,978 Other liabilities 78 8 86 3,315 1,374 111 107 16 4,923 Total liabilities 11,097 1,263 86 107 1,043 11,510 Net assets 14,519 1,435 28 128 1,278 14,518 Equity Capital and reserves attributable to equity holders Share capital 411 411 Share premium account 550 550 Other reserves 1,851 1,851 Retained earnings 11,606 1,417 28 118 1,278 11,613 14,418 1,417 28 118 1,278 14,425 Minority equity interests 101 18 10 93 Total equity and reserves 14,519 1,435 28 128 1,278 14,518 AstraZeneca Annual Report and IFRS Restatements Form 20-F Information 2004 145 Reconciliation of equity IAS 32 Reported IAS 19 IAS 39 IAS 12 under UK Employee Financial Income Restated GAAP Benefits Instruments Tax Other under IFRS As at 31 December 2003 $m $m $m $m $m $m Assets Non-current assets Property, plant and equipment 7,536 11 7,547 Goodwill and intangible assets 2,884 143 3,027 Other investments 220 7 80 133 Deferred tax assets 472 2 1,021 19 1,514 10,640 472 5 1,021 93 12,221 Current assets Inventories 3,022 3,022 Trade and other receivables 5,960 643 897 4,420 Short term investments, cash and cash equivalents 3,951 200 4,151 12,933 643 200 897 11,593 Total assets 23,573 171 195 124 93 23,814 Liabilities Current liabilities Short term borrowings, overdrafts and current instalments of loans 152 152 Other creditors 7,543 143 994 6,406 7,695 143 994 6,558 Non-current liabilities Loans 303 303 Retirement benefit obligations 1,528 1,528 Provisions and deferred tax liabilities 2,266 314 61 132 8 2,153 Other liabilities 52 11 63 2,621 1,214 61 132 19 4,047 Total liabilities 10,316 1,071 61 132 975 10,605 Net assets 13,257 1,242 134 8 1,068 13,209 Equity Capital and reserves attributable to equity holders Share capital 423 423 Share premium account 449 449 Other reserves 1,857 1,857 Retained earnings 10,449 1,242 134 18 1,068 10,391 13,178 1,242 134 18 1,068 13,120 Minority equity interests 79 10 89 Total equity and reserves 13,257 1,242 134 8 1,068 13,209 AstraZeneca Annual Report and IFRS Restatements 146 Form 20-F Information 2004 IFRS Restatements continued Consolidated Cash Flow Statement 2004 2003 For the year ended 31 December $m $m Cash flows from operating activities Operating profit before taxation 4,547 4,007 Depreciation, amortisation and impairment 1,268 1,293 Increase in working capital 9 1,080 Other non-cash movements 326 73 Cash from operating activities 6,132 4,293 Interest paid 69 39 Tax paid 1,246 886 Net cash inflow from operating activities 4,817 3,368 Cash flows from investing activities Disposal of business operations 355 80 Movement in short term investments and fixed deposits 1,855 617 Purchases of property, plant and equipment 1,063 1,282 Disposals of property, plant and equipment 35 38 Purchase of intangible assets 215 293 Purchase of fixed asset investments 117 120 Interest received 119 117 Dividends paid by subsidiaries to minority interests 5 11 Dividends received 6 2 Net cash inflow outflow from investing activities 970 852 Cash flows from financing activities Proceeds from issue of share capital 102 47 Repurchase of shares 2,212 1,154 Increase in repayment of loans 725 345 Dividends paid 1,378 1,222 Increase in short term borrowings 2 Net cash outflow from financing activities 2,761 2,674 Net increase decrease in cash and cash equivalents 3,026 158 Cash and cash equivalents at the beginning of the period 872 968 Exchange movements cash and cash equivalents 29 62 Cash and cash equivalents at the end of the period 3,927 872 Cash and cash equivalents consists of: Cash and cash equivalents 4,067 1,024 Overdrafts 140 152 3,927 872 Reconciliation of Net Cash and Debt 2004 2003 For the year ended 31 December $m $m Increase decrease in cash and cash equivalents 3,026 158 Cash inflow outflow from increase decrease in loans and short term borrowings 727 345 Cash inflow from decrease in short term investments 1,855 617 Change in net funds resulting from cash flows 444 430 Exchange movements cash and debt 34 82 Movement in net funds UK GAAP 478 348 Fair value adjustments 180 13 Movement in net funds 298 361
